465 related articles for article (PubMed ID: 30638768)
21. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
[TBL] [Abstract][Full Text] [Related]
22. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Pothuri B; Han S; Chase DM; Heitz F; Burger RA; Gaba L; Van Le L; Guerra E; Bender D; Korach J; Cloven N; Churruca C; Follana P; DiSilvestro P; Baurain JF; Jardon K; Pisano C; Peen U; Mäenpää J; Gupta D; Bacqué E; Li Y; Compton N; Antonova J; Monk BJ; González-Martín A
Gynecol Oncol; 2024 May; 184():168-177. PubMed ID: 38325276
[TBL] [Abstract][Full Text] [Related]
24. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
25. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Eur J Cancer; 2023 Aug; 189():112908. PubMed ID: 37263896
[TBL] [Abstract][Full Text] [Related]
26.
Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
[TBL] [Abstract][Full Text] [Related]
27. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract][Full Text] [Related]
28. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Musacchio L; Palluzzi E; Di Napoli M; Lauria R; Ferrandina G; Angioli R; Bergamini A; Corrado G; Perniola G; Cassani C; Savarese A; Gori S; Greco F; De Angelis C; Zafarana E; Giannarelli D; Cinieri S; Mosconi AM; Raspagliesi F; Pignata S; Scambia G; Lorusso D
Gynecol Oncol; 2024 May; 184():24-30. PubMed ID: 38277918
[TBL] [Abstract][Full Text] [Related]
29. Niraparib - A promising drug with hematological toxicity.
Patibandla NS; Monga DK
J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
[TBL] [Abstract][Full Text] [Related]
31. The role of niraparib for the treatment of ovarian cancer.
Ethier JL; Lheureux S; Oza AM
Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
[TBL] [Abstract][Full Text] [Related]
32. Niraparib for the treatment of ovarian cancer.
Kanjanapan Y; Lheureux S; Oza AM
Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
[TBL] [Abstract][Full Text] [Related]
33. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
34. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Moore K; Chan JK; Secord AA; Patel MR; Callahan T; Guo W; Zhang ZY
Cancer Chemother Pharmacol; 2019 Apr; 83(4):717-726. PubMed ID: 30680521
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ni J; Cheng X; Zhao Q; Dai Z; Xu X; Guo W; Gu H; Zhou R; Wang Y; Chen X
J Ovarian Res; 2021 May; 14(1):68. PubMed ID: 33993885
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
Ai X; Pan Y; Shi J; Yang N; Liu C; Zhou J; Zhang X; Dong X; He J; Li X; Chen G; Li X; Zhang H; Liao W; Zhang Y; Ma Z; Jiang L; Cui J; Hu C; Wang W; Huang C; Zhao J; Ding C; Hu X; Wang K; Gao B; Song Y; Liu X; Xiong J; Liu A; Li J; Liu Z; Li Y; Wang M; Zhang B; Zhang D; Lu S
J Thorac Oncol; 2021 Aug; 16(8):1403-1414. PubMed ID: 33915252
[TBL] [Abstract][Full Text] [Related]
38. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
[TBL] [Abstract][Full Text] [Related]
39. Niraparib Slows Ovarian Cancer Progression.
Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
Leung JH; Lang HC; Wang SY; Lo HF; Chan AL
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):489-496. PubMed ID: 34241562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
